Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates
Portfolio Pulse from
Ovid Therapeutics (OVID) reported a Q4 loss of $0.13 per share, which was better than the Zacks Consensus Estimate of a $0.16 loss. This is an improvement from the $0.22 loss per share reported a year ago.

March 11, 2025 | 2:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ovid Therapeutics reported a Q4 loss of $0.13 per share, beating the Zacks Consensus Estimate of $0.16. This is an improvement from the previous year's $0.22 loss per share.
The better-than-expected earnings report, with a smaller loss than anticipated, is likely to have a positive short-term impact on OVID's stock price. The improvement from the previous year's loss also adds to the positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100